Long Term Durability and Safety of Dual IO in NSCLC

 

ecancer
Avatar

ASCO 2021 Update on IO in NSCLC: Considering Data From the Key Trials

By ecancer FEATURING Luis Raez
By ecancer FEATURING Luis Raez
60 views
September 2, 2021
0 Comments
Login to view comments. Click here to Login
Long Term Durability and Safety of Dual IO in NSCLC
09:22
Luis Paz-Ares

2021 ASCO Review on Nivo + Ipi vs. Chemo as 1L Treatment for Advance…

09:18
Filippo de Marinis

1L Nivo + Ipi + 2 Cycles of Chemo vs. Chemo Alone (4 Cycles) in mNSC…

11:11
Tom John

2021 ASCO Update on 1L Nivo + Ipi + 2 Cycles of Chemo vs. Chemo Alon…

04:06
ecancer

1L Nivo+Ipi+Chemo for Patients With Advanced NSCLC and Brain Mets: R…

Feat. D. Carbone
05:22
ecancer

ESMO 2021 Updates on 1L Nivo+Ipi for Unresectable Malignant Pleural …

Feat. S. Peters
07:25
ecancer

ASCO 2021 Update on IO in NSCLC: Considering Data From the Key Trials

Feat. L. Raez
31:18
UAB Medicine Hematology and Oncology Highlights 2021

2021 ASCO Updates on Lung Cancer: (Neo)adjuvant Therapy, Metastatic …

Feat. A. Hegde
19:26
Mariam Alexander

Standard 1L Treatment of Advanced NSCLC in 2021: IO Combination &…

20:10
Keck School of Medicine of USC Advancing Knowledge in Multidisciplinary Lung Cancer Care

Epidemiological Shifts in Lung Cancers: Trends in Treatment and Diag…

Feat. E. David
14:53
Northwestern Medicine Oncology and Hematology

Serum Proteomic Signature & Advanced NSCLC: Can It Be Used as an…

Feat. Y. Chae
36:33
CECOG Academy

Neoadjuvant Treatment of NSCLC With Immune CPIs: Biological Understa…

Feat. C. Zielinski
17:55
Keck School of Medicine of USC Advancing Knowledge in Multidisciplinary Lung Cancer Care

USC Updates on RT for mNSCLC: Consolidative Local Therapy

Feat. M. Daly
61:10
Scripps MD Anderson Cancer Center

Advances in the NSCLC Treatment

Feat. M. Kosty
21:04
2022 West Oncology Conference

Metastatic NSCLC: Approaches and Updates

Feat. J. Porter
37:58
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2022

Practical Approach to Selection of Frontline Therapy in NSCLC Withou…

Feat. M. Johnson
07:37
ASCO 2022 Conference Coverage

ASCO 2022 on Clinical and Genomic Characteristics of Pts With Durabl…

Feat. J. Sands
24
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Clinical and Genomic Characteristics …

Feat. J. Sands
01:18
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on ctDNA Shed as a Tool to Select Immune…

Feat. B. Besse
13:01
Nebraska Oncology Society

ASCO 2022 on Immunotherapy Updates in Advanced NSCLC

Feat. J. Brahmer
09:18
ASCO 2022 Conference Coverage

ASCO 2022 3-Year Update From CheckMate 9LA: 1L Nivo + Ipi + 2 Cycles…

Feat. L. Paz-Ares
01:46
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 3-Year Update From CheckMate 9LA: 1L Niv…

Feat. L. Paz-Ares
06:03
Penn Medicine Abramson Cancer Center

Penn Medicine mNSCLC Updates

Feat. M. Marmarelis
10:59
ASCO 2022 Conference Coverage

ASCO 2022 Five-Year Survival Outcomes From CheckMate 227: Nivo + Ipi…

Feat. L. Paz-Ares
01:24
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Five-Year Survival Outcomes From CheckMa…

Feat. L. Paz-Ares
16:37
Lung Cancer Europe (LuCE)

ASCO 2022 Early Stage NSCLC Updates

Feat. J. Naidoo
47:32
Aaron Franke

1L Therapy for Advanced/Metastatic PD-L1 Negative (TPS <1%) NSCLC

10:17
WCLC 2022 Conference Coverage

WCLC 2022 on Modifiable Biomarkers of Response to Immune Checkpoint …

Feat. D. Spakowicz
01:43
WCLC 2022 Conference Coverage

Lecture Summary - WCLC 2022 on Modifiable Biomarkers of Response to …

Feat. D. Spakowicz
17:29
ILCC 2022 Conference Coverage

Neoadjuvant vs. Adjuvant Immunotherapy From the Surgeon's Persp…

Feat. T. Mitsudomi
07:36
ESMO 2022 Conference Coverage

ESMO 2022 on the CheckMate 9LA Study Results: Clinical Outcomes in P…

Feat. T. John
23:21
Giuseppe Banna

Neoadjuvant Chemotherapy and Immunotherapy for NSCLC

08:17
Nicolas Girard

Neoadjuvant Nivo + Platinum-Doublet Chemo vs. Chemo for Resectable (…